Skip to main content

Table 1 Incidence of peripheral and axial disease

From: Early anti-inflammatory intervention ameliorates axial disease in the proteoglycan-induced spondylitis mouse model of ankylosing spondylitis

Treatment (treatment period)

Vehicle (6.5–8)

ETN + PRD (6.5–8)

Vehicle (6.5–12)

ETN + PRD (6.5–12)

Both peripheral and axial disease

80%

14.3% (p = 0.01)

100.0%

62.5% (p = 0.035)

Peripheral disease only

0

14.3%

0.0

25%

Axial disease only

20%

42.9%

0.0

12.5%

Presence of axial disease

100%

57.1% (p = 0.02)

100.0%

75% (p = 0.0015)

Incidence of peripheral disease

80%

28.6%

100%

87.5%

Peripheral disease incidence at treatment commencement

40%

28.6%

57.1%

62.5%

Total number

5

7

7

8

  1. The statistical significance of data was analysed by one-tailed Z-tests compared with vehicle at corresponding time points
  2. Abbreviations: ETN etanercept, PRD prednisolone